• DOI:10.1007/PL00004971
• Corpus ID: 33161109

Inhibition of LTB4 biosynthesis in situ by CGS 23885, a potent 5-lipoxygenase inhibitor, correlates with its pleural fluid concentrations in an experimentally induced rat pleurisy model

@article{Raychaudhuri1997InhibitionOL,
  title={Inhibition of LTB4 biosynthesis in situ by CGS 23885, a potent 5-lipoxygenase inhibitor, correlates with its pleural fluid concentrations in an experimentally induced rat pleurisy model},
  author={Anilbaran Raychaudhuri and Herbert Chertock and James P. Chovan and L S Jones and Earl F. Kimble and Timothy J. Kowalski and Jane V. Peppard and David H. White and Yoshitaka Satoh and Dennis M. Roland},
  journal={Naunyn-Schmiedeberg's Archives of Pharmacology},
  year={1997},
  volume={355},
  pages={470-474}
}

• A. Raychaudhuri, H. Chertock, +7 authors D. Roland
• Published 21 March 1997
• Medicine, Biology
• Naunyn-Schmiedeberg's Archives of Pharmacology

Abstract An intrapleural injection of carrageenan in rats induced LTB4 and LTC4/D4/E4 biosynthesis, exudate formation, and cellular influx in the pleural cavity. An injection of calcium ionophore (A23187, 100nmol) 16–18h after carrageenan injection augmented leukotriene biosynthesis and exudate formation, but not cellular influx. The carrageenan-induced pleurisy model modifid by A23187 administration was used to study the oral effect of CGS 23885 (N-hydroxy-N-[(6-phenoxy-2H-1-benzopyran-3-yl)-methyl]urea), a potent 5-lipoxygenase (5-LO) inhibitor, on inflammatory parameters. CGS 23885 dose-dependently (1 to 30mg/kg) inhibited the enhanced LTB4 and LTC4/D4/E4 (1 to 10mg/kg) biosynthesis, but had no effect on enhanced exudate formation. An inhibitory effect of CGS 23885 of small magnitude on cellular influx due to carrageenan stimulation was seen at 30mg/kg. The concentrations of CGS 23885 in the pleural fluid were dose-related, and a positive correlation (r2=0.989) between pleural fluid concentration of LTB4 and CGS 23885 was observed. The results confirm that CGS 23885 is a specific, orally active 5-LO inhibitor which can achieve concentrations in the pleural cavity sufficient to inhibit production of LTB4 and LTC4/D4/E4 in an ongoing inflammatory response.